Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Cancer will directly affect about one in three of us at some time in our lives. Many more will be touched indirectly as friends and relatives are lost to this devastating collection of often lethal diseases. For years, the only serious treatments for cancer have been surgery, radiotherapy and chemotherapy – slicing, burning and poisoning as some doctors put it. The side effects of such treatments are often worse than the disease itself because of the collateral damage inflicted on the healthy cells of the body.
The prospect of a “paradigm shift” in cancer treatment could hardly be more welcome, then. The hope comes from “immunotherapy”, where the immune system that normally protects us against invading viruses and microbes is stimulated to attack a spreading tumour.
Cancer specialists are cautiously optimistic that immunotherapy could open a new front in the now infamous “war on cancer” declared as long ago as 1971, when President Nixon signed the National Cancer Act, and revitalised in 2009 with President Obama urging scientists to find a “cure for cancer in our time”.
In making cancer immunotherapy its breakthrough of the year, the journal Science emphasises that it does not want to give patients false hope – given the field’s long history of expectations raised and then dashed. But at the same time, the journal makes it clear that a corner has been turned.
As with many medical breakthroughs, however, it may be years yet before patients see real benefits from immunotherapy. And some types of cancer may not respond at all to the treatments we can expect in the coming decade.
Early results from the first clinical trials involving artificial antibodies are promising, but hardly a cause for jubilation. The lives of most patients in the trials seem to have been extended by just a few months – a significant, but still only incremental improvement.
There is also always the risk of drug resistance. Tumours are complex communities of genetically diverse cells that can rapidly evolve to form breakaway rebels resistant to any new drug or treatment.
Even so, there is an inescapable logic to an attempt to use the body’s own defence system to attack tumour cells. Cancer immunotherapy is a technique which holds out much promise. We can only hope that it is fulfilled.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments